初诊甲亢患者肝损害危险因素的研究进展

淑芳 王, 泽芬 卢

摘要


目的：系统理解初诊甲状腺功能亢进症（甲亢）患者肝损害的危险因素，为甲亢肝损害的诊治提供临床依据。方法：论文从甲亢肝损害诊断、危险因素及机制和治疗等方面阐述。结果：年龄、病程、甲状腺重量、甲状腺激素、TRAb、TGAb 和 TPOAb 等均是初诊甲亢患者发生肝损害的危险因素。结论：年龄、病程、甲状腺重量、甲状腺激素、TRAb、TGAb和 TPOAb 等是初诊甲亢患者发生肝损害的危险因素，而性别与甲亢肝损害的关系有待进一步研究。

关键词


甲状腺功能亢进症；肝损害；危险因素

全文:

PDF

参考


MCDERMOTT MT. Hyperthyroidism[J]. Ann Intern Med, 2020,172(7):49-64.

DE LS, LEE SY, BRAVERMAN LE. Hyperthyroidism[J]. Lancet, 2016,388(10047): 906-918.

ZHANG W, WANG X, LI P, et al. Evaluating Hyperthyroidism-In- duced Liver Injury Based on In Situ Fluorescence Imaging of Glu- tathione and Phosphate via Nano-MOFs Sensor[J]. Anal Chem, 2020,92(13):8952-8958.

WANG R, TAN J, ZHANG G, et al. Risk factors of hepatic dys- function in patients with Graves’ hyperthyroidism and the efficacy of 131iodine treatment[J]. Medicine, 2017,96(5):6035.

DE CAMPOS MAZO DF, DE VASCONCELOS GB, PEREIRA MA, et al. Clinical spectrum and therapeutic approach to hepato- cellular injury in patients with hyperthyroidism[J]. Clin Exp Gas- troenterol, 2013(6):9-17.

ROSS DS, BURCH HB, COOPER DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis [J]. Thyroid, 2016, 26(10):1343-1421.

WAFA B, FATEN H, MOUNA E, et al. Hyperthyroidism and hepatic dysfunction: Report of 17 cases[J]. JGH open, 2020,4(5):876-879.

PIANTANIDA E, IPPOLITO S, GALLO D, et al. The interplay between thyroid and liver: implications for clinical practice[J]. J Endocrinol Invest, 2020,43(7):885-899.

景婧,罗生强,宫嫚,等.甲状腺功能亢进症致亚急性肝衰竭1例报 告[J].临床肝胆病杂志,2013,29(9):707-708.

闫瑞红,卢兰玉,周振虎.131I治疗Graves病合并中度肝损害的疗 效观察[J].中华内分泌外科杂志,2015,9(1):67-68.

LI C, TAN J, ZHANG G, et al. Risk factors of hyperthyroidism with hepatic function injury: a 4-year retrospective study[J]. Horm Metab Res, 2015,47(3):209-213.

刘燕晶,张帆.甲状腺功能亢进症性肝损害的发生机制[J].国际 内分泌代谢杂志,2019,39(1):34-35+48.

任留梅,刘萍,卫红艳,等.Graves病甲亢肝损害与免疫因素关系 的探讨[J].实用医学杂志,2011,27(3):463-468.

朱萍,卫红艳,王坤玲,等.Graves病甲状腺功能亢进症性肝损 害的相关因素分析[J].国际内分泌代谢杂志,2017,37(3):164- 167+217.

HE K, HU Y, XU XH, et al. Hepatic dysfunction related to thyro- tropin receptor antibody in patients with Graves’ disease[J]. Exp Clin Endocrinol Diabetes, 2014,122(6):368-372.

DIANA T, BROWN RS, BOSSOWSKI A, et al. Clinical relevance of thyroid-stimulating autoantibodies in pediatric graves’ disease-a mul-ticenter study[J]. J Clin Endocrinol Metab, 2014,99(5):1648-1655.

PONTO KA, KANITZ M, OLIVO PD, et al. Clinical relevance of thyroid-stimulating immunoglobulins in graves’ ophthalmopa-thy[J]. Ophthalmology, 2011,118(11):2279-2285.

GOH SY, HO SC, SEAH LL, et al. Thyroid autoantibody profiles in ophthalmic dominant and thyroid dominant Graves’ disease differ and suggest ophthalmopathy is a multiantigenic disease[J]. Clin Endocrinol (Oxf), 2004,60(5):600-607.

董自蓬,马玲,陈钰琼,等.Graves病患者促甲状腺激素受体抗体与肝功能指标的关系[J].中国现代医学杂志,2020,30(11):43-47.

李承霞,谭建,张桂芝,等.回顾性研究:甲状腺机能亢进症伴肝功能损害危险因素分析[J].中华内分泌代谢杂志,2015,31(6):501-505.

田竹芳,施秉银,赵新,等.Graves病患者甲亢性肝损害

ZHANG R, TIAN X, QIN L, et al. Factors predicting abnormal liver function tests induced by Graves’ disease alone: a retrospec-tive cohort study[J]. Medicine, 2015,94(19):839.

ZIMMERMANN MB, ITO Y, HESS SY, et al. High thyroid vol- ume in children with excess dietary iodine intakes[J]. Am J Clin Nutr, 2005,81(4):840-844.

刘然,杨倩琳,赵丽,等.1221例未治疗成年Graves病患者肝功能指标异常情况

ZHANG Q, LIU SZ, GUAN YX, et al. RNASET2, GPR174, and PTPN22 gene polymorphisms are related to the risk of liver dam- age associated with the hyperthyroidism in patients with Graves’ disease[J]. Clin Lab Anal, 2018,32(2):22258.

KAHALY GJ, BARTALENA L, HEGEDUS L, et al. 2018 Eu- ropean thyroid association guideline for the management of Graves’hyperthyroidism[J]. Eur Thyroid J, 2018,7(4):167-186.

武应芳,郭进新,王利兵,等.普萘洛尔联合甲巯咪唑对甲状腺功 能亢进症患者的心率

尹亮,谭建,王任飞.131I治疗合并肝损害Graves甲亢840例疗效分 析[J].中华核医学与分子影像学杂志,2012,32(6):426-429.

ZHANG Q, GUAN Y, XIANG T, et al. Combination of molecular adsorbent recirculating system and radioiodine for the treatment of concurrent hyperthyroidism and severe liver dysfunction:a retro- spective cohort study[J]. Endocr Pract, 2017,23(2):141-148.

DING Y, XING J, FANG Y, et al. 131I therapy for 345 patients with refractory severe hyperthyroidism:Without antithyroid drug pre- treatment[J]. Exp Biol Med(Maywood), 2016,241(3):290-295.




DOI: https://doi.org/10.12346/pmr.v4i3.6697

Refbacks

  • 当前没有refback。